How does USPSTF handle screening tests with low specificity?

• A. Ignoring false positives
• B. Weigh harms from false positives, and may lead to weaker recommendations or revisions
• C. Always recommend screening regardless of specificity
• D. Only consider sensitivity

Answer: (B)

Screening recommendations are driven by balancing benefits with harms, including the harms that arise when a test has low specificity. When specificity is low, many individuals without the disease receive a positive result (false positives), leading to unnecessary follow-up tests, invasive procedures, anxiety, potential complications, and possible overtreatment. Those downsides can outweigh the actual health benefits of screening, especially if the disease detected by screening would not have caused harm during the patient’s lifetime or if effective treatment is not substantially better than no treatment. In such cases, the USPSTF may issue weaker recommendations or call for revisions to reflect the unfavorable balance between benefits and harms. They do not ignore false positives, they do not always recommend screening regardless of specificity, and they consider both sensitivity and specificity along with downstream consequences, not just one metric.